Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis

Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis....

Descripción completa

Detalles Bibliográficos
Autores principales: Kosaka, Atsushi, Sakamoto, Naoya, Hikone, Mayu, Imai, Kazuo, Ota, Masayuki, Washino, Takuya, Maeda, Takuya, Iwabuchi, Sentarou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270753/
https://www.ncbi.nlm.nih.gov/pubmed/32378656
http://dx.doi.org/10.2169/internalmedicine.4096-19
_version_ 1783541952585662464
author Kosaka, Atsushi
Sakamoto, Naoya
Hikone, Mayu
Imai, Kazuo
Ota, Masayuki
Washino, Takuya
Maeda, Takuya
Iwabuchi, Sentarou
author_facet Kosaka, Atsushi
Sakamoto, Naoya
Hikone, Mayu
Imai, Kazuo
Ota, Masayuki
Washino, Takuya
Maeda, Takuya
Iwabuchi, Sentarou
author_sort Kosaka, Atsushi
collection PubMed
description Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.
format Online
Article
Text
id pubmed-7270753
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-72707532020-06-09 Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis Kosaka, Atsushi Sakamoto, Naoya Hikone, Mayu Imai, Kazuo Ota, Masayuki Washino, Takuya Maeda, Takuya Iwabuchi, Sentarou Intern Med Case Report Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option. The Japanese Society of Internal Medicine 2020-05-01 2020-05-01 /pmc/articles/PMC7270753/ /pubmed/32378656 http://dx.doi.org/10.2169/internalmedicine.4096-19 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Kosaka, Atsushi
Sakamoto, Naoya
Hikone, Mayu
Imai, Kazuo
Ota, Masayuki
Washino, Takuya
Maeda, Takuya
Iwabuchi, Sentarou
Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title_full Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title_fullStr Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title_full_unstemmed Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title_short Failure of Liposomal-amphotericin B Treatment for New World Cutaneous Leishmaniasis due to Leishmania braziliensis
title_sort failure of liposomal-amphotericin b treatment for new world cutaneous leishmaniasis due to leishmania braziliensis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270753/
https://www.ncbi.nlm.nih.gov/pubmed/32378656
http://dx.doi.org/10.2169/internalmedicine.4096-19
work_keys_str_mv AT kosakaatsushi failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT sakamotonaoya failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT hikonemayu failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT imaikazuo failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT otamasayuki failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT washinotakuya failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT maedatakuya failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis
AT iwabuchisentarou failureofliposomalamphotericinbtreatmentfornewworldcutaneousleishmaniasisduetoleishmaniabraziliensis

Ejemplares similares